University of Nottingham
Nottingham, Nottinghamshire, NG7 2RD, United Kingdom
NCT Number: NCT02217605
The purpose of this study is to determine the effects of an oral fructose challenge on liver adenosine triphosphate (ATP) reserves using 31P magnetic resonance spectroscopy (MRS) as a potential measure measure of liver health.
Looking for future studies?
Notify Me18 year–30 year
Male
Interventional
Not applicable
Nottingham, Nottinghamshire, NG7 2RD, United Kingdom
This study uses 31P spectra acquired from the liver in healthy subjects following a fructose drink to monitor ATP levels. This is also related to baseline BMI, liver glycogen and liver lipid levels
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Oral Fructose Challenge (75 g fructose in 500 ml water) following overnight fast
Time frame: 2 hours post prandial
Monitor hepatic ATP levels following an oral fructose challenge using 31P magnetic resonance spectroscopy
Time frame: 2 hours post prandial
Measure baseline liver lipid and glycogen using magnetic resonance spectroscopy and correlate BMI, lipid and glycogen levels with rate of ATP depletion and recovery following an oral fructose challenge
Stephen Bawden
Other
Investigating the Effects of an Oral Fructose Challenge on Hepatic ATP Reserves in Healthy Volunteers
Acronym: 31PMRS_FRU
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04692025
Digestive System Diseases, Dyslipidemias
Changsha, Hunan, China
View Trial DetailsNCT04845646
Digestive System Diseases, Fatty Liver
San Antonio, Texas, United States
View Trial DetailsNCT04427917
Digestive System Diseases, Fatty Liver
Brussels, Bruxelles-capitale, Région de, Belgium
View Trial DetailsNCT03976687
Digestive System Diseases, Fatty Liver
Randwick, New South Wales, Australia
View Trial Details